Non-Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two-Sample Bidirectional Mendelian Randomisation Study.

What Was Tested

This observational study looks at Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes.

As Mendelian randomisation (MR) avoids many limitations of conventional observational studies, this two-sample bidirectional MR analysis was conducted to determine the following: (i) whether genetically predicted 25-hydroxyvitamin D [25(OH)D] levels are a risk factor for NAFLD, and (ii) whether genetic risk for NAFLD influences 25(OH)D levels.

Why It Was Studied

Evidence for a role for vitamin D in non-alcoholic fatty liver disease (NAFLD) pathogenesis is conflicting.

These GWASs were done both without (primary analysis) and with (sensitivity analysis) the population-level exclusion of other liver diseases (e.g., alcoholic liver diseases, toxic liver diseases, viral hepatitis, etc.).

What Was Measured

These GWASs were done both without (primary analysis) and with (sensitivity analysis) the population-level exclusion of other liver diseases (e.g., alcoholic liver diseases, toxic liver diseases, viral hepatitis, etc.).

The subject headings attached to it are Non-alcoholic Fatty Liver Disease, Biological Specimen Banks, Genome-Wide Association Study, Vitamin D, Vitamins, Polymorphism, Single Nucleotide and United Kingdom.

The authors tagged it with the keywords 25(OH)D, GWAS, MR, Mendelian randomization, NAFLD and UK Biobank.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc in people with fatty liver & elevated liver enzymes.

The publication is from 2023 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.